Is Eli Lilly Alzheimer's medication about to be approved? Supported by FDA advisory panel, with a market value exceeding $800 billion for the first time
海角七号
发表于 2024-6-11 16:18:56
209
0
0
The Alzheimer's drug donanemab from pharmaceutical giant Eli Lilly is about to receive a green light from US regulatory agencies.
The advisory committee of 11 independent experts convened by the US Food and Drug Administration (FDA) unanimously voted that donanemab is an "effective" drug for treating Alzheimer's disease, and the benefits of this experimental treatment outweigh the risks.
Stronger therapeutic effect
Lilly's donamab is a new treatment method that slows down cognitive decline in early Alzheimer's disease patients by removing amyloid plaques associated with the disease.
For a long time, analysts have predicted that donanemab will surpass the only existing Alzheimer's disease treatment drug, Leqembi, because donanemab has higher efficacy in clinical trials and only needs to be administered once a month instead of every two weeks.
In the Phase III trial, compared to the placebo group, Leqembi slowed down cognitive decline by 27%, while Donanemab slowed down cognitive decline by 35%.
However, donanemab and similar drugs have safety issues related to brain swelling and cerebral hemorrhage, and three patients died due to brain swelling events.
In March of this year, the FDA requested a review of the drug and delayed its approval due to concerns about its safety as it may cause brain swelling. The FDA has decided to convene an external expert meeting to discuss the safety and efficacy of its drugs.
More data needed
Although the FDA's external advisory committee has recognized donanemab, the FDA still points out that more data is needed to understand the impact of the drug on patients with low or no Tau protein levels, as Lilly has excluded these patients from clinical trials.
Tau protein is a protein associated with Alzheimer's disease, and its level is one of the core indicators for diagnosing Alzheimer's disease.
Committee member and Cornell University professor Costantino Iadecola said, "If some subgroups require further analysis, then this drug should not be hindered from being made available to the public."
Nilufer Ertekin Taner, a neurogeneticist at the Mayo Foundation, stated that more data is needed for certain groups, such as those with Down syndrome.
The recommendations of this committee are not binding, but the FDA typically follows the recommendations of such committees.
Boosting stock prices
The support of this advisory committee is a boost for this pharmaceutical giant.
As of Monday's close, the company's stock price closed up 1.8%. On that day, the stock price reached a historic high, with a market value exceeding 800 billion US dollars.
Mark Mintun, Vice President of Neuroscience Research and Development at Lilly, stated that the company is "pleased that the committee unanimously recognizes Donanemab's pros and cons comparison.".
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Top 20 US stock transactions: Trump Media Technology Group's stock price surged by 12%; Nvidia once became the world's most valuable company during trading
- NVIDIA overtakes Apple to become the world's largest company by market value
- AI chip giant NVIDIA's market value exceeds Apple's, TSMC previously stated that AI demand is' just beginning '
- Which demon stock is so strong? Nvidia, which has returned to the top of the global market capitalization chart, has been surpassed on the increase chart
- Nvidia's market value exceeds $3.6 trillion, breaking the history of the US stock market
- AI Weekly | AI search startup Perplexity valuation surges to $9 billion; Nvidia's market value exceeds Apple's
- Over 12 trillion yuan! Bitcoin market value exceeds silver, Tesla returns nearly 4 billion yuan, related ETF draws 24.6 billion yuan in four days
- Global market: Three major US stock indices collectively close down, Tesla falls nearly 6%, market value returns below $1 trillion
- A chip giant with a market value of 1.6 trillion yuan plans to lay off employees worldwide, and its stock price has fallen nearly 20% in the past month!
- Financial analysis: Market value fluctuation may exceed $300 billion. NVIDIA's financial report tonight is highly anticipated
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏
-
【ナスダック中国金龍指数は1%下落した。人気の中概株の多くは下落した】現地時間11月21日、ナスダック中国金龍指数は1%下落し、人気の中概株の多くは下落し、必死に10%超下落し、愛奇芸は7%超下落し、百度は6%近く ...
- 比尔992
- 昨天 11:57
- 支持
- 反对
- 回复
- 收藏